Liquidia Co. (NASDAQ:LQDA) Insider Rajeev Saggar Sells 1,649 Shares

Liquidia Co. (NASDAQ:LQDA) insider Rajeev Saggar sold 1,649 shares of the firm’s stock in a transaction that occurred on Friday, April 19th. The stock was sold at an average price of $13.68, for a total transaction of $22,558.32. Following the completion of the transaction, the insider now directly owns 211,672 shares of the company’s stock, valued at $2,895,672.96. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Liquidia Stock Performance

Liquidia stock opened at $12.95 on Wednesday. The firm’s fifty day moving average price is $14.64 and its 200-day moving average price is $11.17. The stock has a market cap of $984.59 million, a P/E ratio of -10.79 and a beta of 0.16. Liquidia Co. has a fifty-two week low of $5.71 and a fifty-two week high of $16.99.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Wednesday, March 13th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.19). The company had revenue of $4.53 million for the quarter, compared to analysts’ expectations of $5.29 million. Liquidia had a negative net margin of 448.89% and a negative return on equity of 132.16%. On average, analysts predict that Liquidia Co. will post -1.01 earnings per share for the current year.

Institutional Trading of Liquidia

Institutional investors and hedge funds have recently made changes to their positions in the stock. Fortitude Family Office LLC purchased a new stake in shares of Liquidia during the 4th quarter valued at $26,000. Aigen Investment Management LP bought a new position in shares of Liquidia during the 3rd quarter valued at $80,000. SG Americas Securities LLC bought a new position in shares of Liquidia during the 3rd quarter valued at $84,000. Tower Research Capital LLC TRC grew its holdings in shares of Liquidia by 610.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,997 shares of the company’s stock valued at $108,000 after purchasing an additional 7,731 shares during the last quarter. Finally, Simplicity Solutions LLC bought a new position in shares of Liquidia during the 3rd quarter valued at $136,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Wall Street Analyst Weigh In

LQDA has been the subject of several analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Liquidia in a report on Wednesday, April 10th. HC Wainwright increased their target price on shares of Liquidia from $16.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, March 14th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Liquidia currently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).